Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lukang saltuzumab ± bevacizumab for TROP2-high peritoneal metastatic gastric/colorectal cancer
ChiCTR2600119416Phase 2Not yet recruiting
- Sponsor
- Beijing Luhe Hospital
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of saltuzumab and bevacizumab in gastric cancer (GC), colorectal cancer (CRC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Beijing Luhe Hospital. Primary endpoints: Objective Response Rate, Disease Control Rate and 2 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
saltuzumabbevacizumab
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2600119416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119416.